Advanced in Familial Hemiplegic Migraine

Dr. Lora J. Mcgill

Neurology
6401 Poplar Ave, Suite 420, 
Memphis, TN 
Advanced in Familial Hemiplegic Migraine
6401 Poplar Ave, Suite 420, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lora Mcgill is a Neurologist in Memphis, Tennessee. Dr. Mcgill is rated as an Advanced provider by MediFind in the treatment of Familial Hemiplegic Migraine. Her top areas of expertise are Migraine with Brainstem Aura, Familial Hemiplegic Migraine, Migraine, and Alzheimer's Disease.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Familial Hemiplegic Migraine.

Specialties
Neurology
Licenses
Psychiatry & Neurology in TN
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

6401 Poplar Ave, Suite 420, Memphis, TN 38119

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
LY2951742 Biomarker Study in Patients With Migraine
LY2951742 Biomarker Study in Patients With Migraine
Enrollment Status: Completed
Publish Date: April 09, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
View 9 Less Clinical Trials

2 Total Publications

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
Journal: Headache
Published: October 18, 2021
Similar Doctors
Experienced in Familial Hemiplegic Migraine
Dr. Barbara C. Obrien
Neurology
Experienced in Familial Hemiplegic Migraine
Dr. Barbara C. Obrien
Neurology

Neurology Clinic, PC

8000 Centerview Pkwy, Suite 500, 
Cordova, TN 
 (3.7 miles away)
901-747-1111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Barbara Obrien is a Neurologist in Cordova, Tennessee. Dr. Obrien is rated as an Advanced provider by MediFind in the treatment of Familial Hemiplegic Migraine. Her top areas of expertise are Migraine, Benign Rolandic Epilepsy, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, and Thromboangiitis Obliterans. Dr. Obrien is currently accepting new patients.

Experienced in Familial Hemiplegic Migraine
Dr. David L. Pritchard
Neurology
Experienced in Familial Hemiplegic Migraine
Dr. David L. Pritchard
Neurology

Neurology Clinic, PC

8000 Centerview Pkwy, Suite 500, 
Cordova, TN 
 (3.7 miles away)
901-747-1111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Pritchard is a Neurologist in Cordova, Tennessee. Dr. Pritchard is rated as an Advanced provider by MediFind in the treatment of Familial Hemiplegic Migraine. His top areas of expertise are Alzheimer's Disease, Memory Loss, Essential Tremor, and Migraine. Dr. Pritchard is currently accepting new patients.

Experienced in Familial Hemiplegic Migraine
Dr. Salman Saeed
Neurology
Experienced in Familial Hemiplegic Migraine
Dr. Salman Saeed
Neurology

Office

6570 Stage Rd Ste 202, 
Bartlett, TN 
 (5.3 miles away)
901-213-4225
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Salman Saeed is a Neurologist in Bartlett, Tennessee. Dr. Saeed is rated as a Distinguished provider by MediFind in the treatment of Familial Hemiplegic Migraine. His top areas of expertise are Epilepsy, Seizures, Memory Loss, and Stroke.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcgill's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile